结核病mRNA疫苗的研制策略与展望

doi:10.19982/j.issn.1000-6621.20240086

摘要/Abstract

摘要：

应对危害全球人类健康的重大传染性疾病——结核病流行的严峻挑战,迫切需要研制出有效的新型结核病疫苗。虽然目前开展了多种类型的新型结核病疫苗的研制,且一些疫苗已进入临床试验研究,但至今仍未能获得可以替代传统卡介苗(BCG)的更为有效的新型疫苗。随着mRNA疫苗研制技术的突破,其研发周期短、高效、安全和生产成本低等优点,使其成为一个非常有前景的疫苗研发新方向。笔者主要就mRNA疫苗的技术原理、优势、制备技术,以及结核病mRNA疫苗的研制策略和现状等方面的研究进展进行综述,以期为结核病mRNA疫苗的研制提供参考。

关键词: 分枝杆菌,结核, RNA, 细菌, RNA, 信使, 疫苗, 灭活, 策略, 实验性, 综述

Abstract:

To deal with the serious challenge of the epidemic of tuberculosis (TB) epidemic, a major infectious disease that endangers global human health, there is urgent need to develop an effective new TB vaccine. Although lots of types of new TB vaccines are currently being developed, and some of vaccines have entered clinical trials, a more effective new TB vaccine that can replace the traditional BCG vaccine has not yet been obtained. With the breakthrough of mRNA vaccine development technology, its advantages of short development cycle, high efficiency, safety and low production cost make it a very promising new direction of vaccine research and development. In this paper, the research progress of the technical principle, advantages and preparation techniques of mRNA vaccine, and the development strategy and the current situation of TB-mRNA vaccine was reviewed, so as to provide reference for the development of TB-mRNA vaccine.

Key words: Mycobacterium tuberculosis, RNA, bacterial, RNA, messenger, Vaccines, inactivated, Games, experimental, Review

中图分类号:

R392.9

杨静, 肖丽娟, 方谭玮. 结核病mRNA疫苗的研制策略与展望[J]. 中国防痨杂志, 2024, 46(5): 590-595. doi: 10.19982/j.issn.1000-6621.20240086

Yang Jing, Xiao Lijuan, Fang Tanwei. Development strategy and prospect of tuberculosis mRNA vaccines[J]. Chinese Journal of Antituberculosis, 2024, 46(5): 590-595. doi: 10.19982/j.issn.1000-6621.20240086

图/表 2

参考文献 37

[1]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	陈伟, 孙慧娟, 赵雁林. 新时期我国结核病防治服务体系建设及展望. 结核与肺部疾病杂志, 2024, 5(2): 95-100. doi:10.19983/j.issn.2096-8493.2024025.
[3]	Romano M, Squeglia F, Kramarska E, et al. A Structural View at Vaccine Development against M.tuberculosis. Cells, 2023, 12(2): 317. doi:10.3390/cells12020317.
[4]	Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis, 2020, 20(3): e28-e37. doi:10.1016/S1473-3099(19)30625-5. pmid: 32014117
[5]	Looney MM, Hatherill M, Musvosvi M, et al. Conference report: WHO meeting summary on mRNA-based tuberculosis vaccine development. Vaccine, 2023, 41(48): 7060-7066. doi:10.1016/j.vaccine.2023.10.026.
[6]	Rohner E, Yang R, Foo KS, et al. Unlocking the promise of mRNA therapeutics. Nat Biotechnol, 2022, 40(11): 1586-1600. doi:10.1038/s41587-022-01491-z. pmid: 36329321
[7]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[8]	Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science, 1990, 247(4949 Pt 1): 1465-1468. doi:10.1126/science.1690918. pmid: 1690918
[9]	袁军鸿, 杨昭庆. mRNA疫苗的研究进展. 中国生物制品学杂志, 2022, 35(6): 734-739.
[10]	Kon E, Elia U, Peer D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol, 2022, 73: 329-336. doi:10.1016/j.copbio.2021.09.016.
[11]	Shahrear S, Islam ABMMK. Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of Mycobacterium tuberculosis. Mol Divers, 2023, 27(4): 1613-1632. doi:10.1007/s11030-022-10515-4.
[12]	Rosa SS, Prazeres DMF, Azevedo AM, et al. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine, 2021, 39(16): 2190-2200. doi:10.1016/j.vaccine.2021.03.038. pmid: 33771389
[13]	董文彬, 张雪梅, 陈一飞. mRNA疫苗核酸修饰与递送系统的发展历程与挑战. 中国医药工业杂志, 2023, 54(3): 304-311. doi:10.16522/j.cnki.cjph.2023.03.002.
[14]	Pal R, Bisht MK, Mukhopadhyay S. Secretory proteins of Mycobacterium tuberculosis and their roles in modulation of host immune responses: focus on therapeutic targets. FEBS J, 2022, 289(14): 4146-4171. doi:10.1111/febs.16369.
[15]	Al-Attiyah R, Mustafa AS. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect Immun, 2008, 76(9): 4190-4198. doi:10.1128/IAI.00199-08. pmid: 18573897
[16]	Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Signal Transduct Target Ther, 2023, 8 (1): 341. doi:10.1038/s41392-023-01561-x.
[17]	Xie C, Yao R, Xia X. The advances of adjuvants in mRNA vaccines. NPJ Vaccines, 2023, 8(1): 162. doi:10.1038/s41541-023-00760-5. pmid: 37884526
[18]	傅佳燕, 冯硕, 杜彬荷, 等. mRNA疗法的研究进展与挑战. 中国科学: 生命科学, 2023, 53(1): 30-49.
[19]	Jamous YF, Alhomoud DA. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2. Cureus, 2023, 15(9): e45602. doi:10.7759/cureus.45602.
[20]	秦凤铭, 任宁, 成温玉, 等. 传染病mRNA疫苗的研究进展及应用. 生物工程学报, 2023, 39(10): 3966-3984. doi:10.13345/j.cjb.230273.
[21]	Yang J, Zhu J, Sun J, et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Mol Ther Nucleic Acids, 2022, 30: 184-197. doi:10.1016/j.omtn.2022.09.010.
[22]	Yousefi Avarvand A, Khademi F, Tafaghodi M, et al. The roles of latency-associated antigens in tuberculosis vaccines. Indian J Tuberc, 2019, 66 (4): 487-491. doi:10.1016/j.ijtb.2019.04.012. pmid: 31813436
[23]	Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology, 2018, 23(4): 359-368. doi:10.1111/resp.13245. pmid: 29341430
[24]	Hia F, Takeuchi O. The effects of codon bias and optimality on mRNA and protein regulation. Cell Mol Life Sci, 2021, 78(5): 1909-1928. doi:10.1007/s00018-020-03685-7. pmid: 33128106
[25]	Hanson G, Coller J. Codon optimality, bias and usage in translation and mRNA decay. Nat Rev Mol Cell Biol, 2018, 19(1): 20-30. doi:10.1038/nrm.2017.91.
[26]	Lampson BC, Inouye S, Inouye M. msDNA of bacteria. Prog Nucleic Acid Res Mol Biol, 1991, 40: 1-24. doi:10.1016/s0079-6603(08)60838-7.
[27]	To KKW, Cho WCS. An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opin Drug Discov, 2021, 16(11): 1307-1317. doi:10.1080/17460441.2021.1935859.
[28]	Chaney JL, Clark PL. Roles for Synonymous Codon Usage in Protein Biogenesis. Annu Rev Biophys, 2015, 44: 143-166. doi:10.1146/annurev-biophys-060414-034333. pmid: 25747594
[29]	Gebre MS, Brito LA, Tostanoski LH, et al. Novel approaches for vaccine development. Cell, 2021, 184(6): 1589-1603. doi:10.1016/j.cell.2021.02.030. pmid: 33740454
[30]	Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv Drug Deliv Rev, 2020, 154-155: 37-63. doi:10.1016/j.addr.2020.06.002.
[31]	苗佳颖, 陆伟. 应用于mRNA疫苗的非病毒载体递送系统研究进展. 药学进展, 2022, 46(2): 84-92.
[32]	Picon MA, Wang L, Da Fonseca Ferreira A, et al. Extracellular Vesicles as Delivery Systems in Disease Therapy. Int J Mol Sci, 2023, 24(24): 17134. doi:10.3390/ijms242417134.
[33]	金盈圻, 王宗保, 王川. 衣原体mRNA疫苗的研发对策与展望. 中国人兽共患病学报, 2022, 38(4): 349-358. doi:10.3969/j.issn.1002-2694.2022.00.032.
[34]	夏敏, 杨晓岚, 杨鹏辉, 等. 结核分枝杆菌Ag85B-mRNA疫苗的体外合成及其免疫原性研究. 免疫学杂志, 2019, 35(5): 404-408. doi:10.13431/j.cnki.immunol.j.20190061.
[35]	World Health Organization. TB Research Tracker. Geneva: World Health Organization, 2023.
[36]	健康报. 新型结核病疫苗,何时走进现实[EB/OL]. [2023-07-25]. https://www.thepaper.cn/newsDetail_forward_23978724.
[37]	高嘉淇, 赵献军, 华进联. mRNA疫苗在人和动物重大疫病防控中的研究进展. 生理学报, 2023, 75(5): 647-658. doi:10.13294/j.aps.2023.0058.